Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...
WWLP Springfield on MSN4d
New Bedford man sentenced to prison for stealing veteran’s disability benefitsA New Bedford man was sentenced to prison in federal court on Friday for stealing over $450,000 in disability benefits that ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
The Standard-Times on MSN1d
New Bedford man stole over $450K from disabled veteran. Here's what we know.Hundreds of thousands in monthly veteran benefits were stolen by New Bedford man. Here's what he was sentenced: ...
When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...
Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback